These results were very encouraging and led us to believe that the antibody could be utilized as an ADC product. A plan to develop this potential product is being created and the 5B1-based ADC will be positioned as a follow-on product to the full-length antibody. " The Company's early work in combining the 5B1 antibody with a radiolabel for development of a novel Positron Emission Tomography (PET) imaging agent for detection and assessment of pancreatic cancer was published as the cover article in the Journal of Nuclear Medicine (J Nucl Med 3013;54:1-7). The work described in this article was the basis for the Company's successful National Cancer Institute contract award of $1.5 Million that the Company announced on August 25, 2014. About Telik and MabVax, Post-Merger On July 8, 2014, Telik, Inc. merged with MabVax Therapeutics, Inc., a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer.